The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer’s Disease

被引:0
|
作者
Xianbo Zhuang [1 ]
Jie Lin [2 ]
Yamin Song [3 ]
Ru Ban [1 ]
Xin Zhao [1 ]
Zhangyong Xia [1 ]
Zheng Wang [1 ]
Guifeng Zhang [4 ]
机构
[1] Liaocheng People’s Hospital and Liaocheng Hospital Affiliated to Shandong First Medical University,Department of Neurology
[2] Shandong University,School of Basic Medicine Sciences
[3] Liaocheng People’s Hospital,Department of Joint Laboratory for Translational Medicine Research
[4] Liaocheng People’s Hospital,Department of Neurology
[5] Shandong University,Department of Neurology
[6] the Second People’s Hospital of Liaocheng,Department of Neurosurgery
[7] Liaocheng Traditional Chinese Medicine Hospital,undefined
关键词
Alzheimer’s disease; PANoptosis; Amyloid-beta; Tau protein; Inflammation; Therapeutic strategy;
D O I
10.1007/s12017-024-08815-z
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder, and the vast majority of cases occur in elderly patients. Recently, the accumulation of Aβ and tau proteins has drawn considerable attention in AD research. This review explores the multifaceted interactions between these proteins and their contribution to the pathological landscape of AD, encompassing synaptic dysfunction, neuroinflammation, and PANoptosis. PANoptosis is a collective term for programmed cell death (PCD) modalities that encompass elements of apoptosis, pyroptosis, and necroptosis. The accumulation of Aβ peptides and tau proteins, along with the immune response in brain cells, may trigger PANoptosis, thus advancing the progression of the disease. Recent advancements in molecular imaging and genetics have provided deeper insights into the interactions between Aβ peptides, tau proteins, and the immune response. The review also discusses the role of mitochondrial dysregulation in AD. The exploration of the interplay between neurodegeneration, immune responses, and cell death offers promising avenues for the development of innovative treatments.
引用
收藏
相关论文
共 50 条
  • [21] Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer's Disease Associated with Down Syndrome
    Ichimata, Shojiro
    Martinez-Valbuena, Ivan
    Lee, Seojin
    Li, Jun
    Karakani, Ali M.
    Kovacs, Gabor G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [22] Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
    Sadigh-Eteghad, Saeed
    Sabermarouf, Babak
    Majdi, Alireza
    Talebi, Mahnaz
    Farhoudi, Mehdi
    Mahmoudi, Javad
    MEDICAL PRINCIPLES AND PRACTICE, 2015, 24 (01) : 1 - 10
  • [23] Alzheimer's disease - The ins and outs of amyloid-beta
    Beyreuther, K
    Masters, CL
    NATURE, 1997, 389 (6652) : 677 - 678
  • [24] Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease
    Murphy, M. Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04): : 391 - 392
  • [25] Plasma amyloid-beta oligomer and phosphorylated tau:diagnostic tools for progressive Alzheimer's disease
    Seong Soo A.An
    John P.Hulme
    Neural Regeneration Research, 2023, (11) : 2391 - 2392
  • [26] Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons
    Rajmohan, Ravi
    Reddy, P. Hemachandra
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 57 (04) : 975 - 999
  • [27] Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
    Takechi, R.
    Galloway, S.
    Pallebage-Gamarallage, M. M. S.
    Mamo, J. C. L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (02) : 19 - 25
  • [28] Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer's disease
    An, Seong Soo A.
    Hulme, John P.
    NEURAL REGENERATION RESEARCH, 2023, 18 (11) : 2391 - 2392
  • [29] Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
    Gustavo Patow
    Leon Stefanovski
    Petra Ritter
    Gustavo Deco
    Xenia Kobeleva
    Alzheimer's Research & Therapy, 15
  • [30] Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease
    Zhang, Wei
    Smith, Nathan
    Zhou, Yiqun
    McGee, Caitlin M.
    Bartoli, Mattia
    Fu, Shiwei
    Chen, Jiuyan
    Domena, Justin B.
    Joji, Annu
    Burr, Hannah
    Lv, Guohua
    Cilingir, Emel K.
    Bedendo, Susanna
    Claure, Matteo L.
    Tagliaferro, Alberto
    Eliezer, David
    Veliz, Eduardo A.
    Zhang, Fuwu
    Wang, Chunyu
    Leblanc, Roger M.
    ACTA BIOMATERIALIA, 2024, 183 : 341 - 355